[HTML][HTML] Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma
K Allmeroth, M Horn, V Kroef, S Miethe, RU Müller… - Leukemia, 2021 - nature.com
Multiple myeloma (MM) is an incurable disease characterized by clonal expansion of
malignant plasma cells in the bone marrow [1]. Although the advent of novel therapeutics …
malignant plasma cells in the bone marrow [1]. Although the advent of novel therapeutics …
Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma.
K Allmeroth, M Horn, V Kroef, S Miethe, RU Müller… - Leukemia, 2021 - go.gale.com
Multiple myeloma (MM) is an incurable disease characterized by clonal expansion of
malignant plasma cells in the bone marrow [1]. Although the advent of novel therapeutics …
malignant plasma cells in the bone marrow [1]. Although the advent of novel therapeutics …
[引用][C] Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma
K Allmeroth, M Horn, V Kroef, S Miethe, RU Mueller… - Leukemia - kups.ub.uni-koeln.de
[HTML][HTML] Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma
K Allmeroth, M Horn, V Kroef, S Miethe, RU Müller… - Leukemia, 2021 - ncbi.nlm.nih.gov
Multiple myeloma (MM) is an incurable disease characterized by clonal expansion of
malignant plasma cells in the bone marrow [1]. Although the advent of novel therapeutics …
malignant plasma cells in the bone marrow [1]. Although the advent of novel therapeutics …
[引用][C] Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma
K Allmeroth, M Horn, V Kroef, S Miethe, RU Muller… - Leukemia, 2020 - pure.mpg.de
Bortezomib resistance mutations in PSMB5 determine response to second-generation
proteasome inhibitors in multiple myeloma :: MPG.PuRe Deutsch Hilfe Datenschutzhinweis …
proteasome inhibitors in multiple myeloma :: MPG.PuRe Deutsch Hilfe Datenschutzhinweis …
Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma.
K Allmeroth, M Horn, V Kroef, S Miethe, RU Müller… - Leukemia, 2020 - europepmc.org
Multiple myeloma (MM) is an incurable disease characterized by clonal expansion of
malignant plasma cells in the bone marrow [1]. Although the advent of novel therapeutics …
malignant plasma cells in the bone marrow [1]. Although the advent of novel therapeutics …
[引用][C] Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma
K Allmeroth, M Horn, V Kroef, S Miethe… - …, 2021 - pubmed.ncbi.nlm.nih.gov
Bortezomib resistance mutations in PSMB5 determine response to second-generation
proteasome inhibitors in multiple myeloma Bortezomib resistance mutations in PSMB5 determine …
proteasome inhibitors in multiple myeloma Bortezomib resistance mutations in PSMB5 determine …
Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma.
K Allmeroth, M Horn, V Kroef, S Miethe, RU Müller… - Leukemia, 2020 - europepmc.org
Multiple myeloma (MM) is an incurable disease characterized by clonal expansion of
malignant plasma cells in the bone marrow [1]. Although the advent of novel therapeutics …
malignant plasma cells in the bone marrow [1]. Although the advent of novel therapeutics …
[引用][C] Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma
K Allmeroth, M Horn, V Kroef, S Miethe, RU Mueller… - Leukemia - kups.ub.uni-koeln.de